Deprenyl
MAO-B inhibitor / Potent inhibitor of monoamine oxidase B (MAO- B) which has been used for the treatment of Parkinson’s disease.1,2 Displays neuroprotective effects rescuing nigral dopaminergic neurons after systemic MPTP treatment.3 Rescues PC12 cells from trophic withdrawal-induced apoptosis.4 Glyceraldehyde-3-phosphate dehydrogenase has been found to be the putative target responsible for its neuroprotective effects.5
Biochemicals & reagents
14611-52-0
Selegiline
Gerlach et al. (1992), The molecular pharmacology of L-deprenyl; Eur. J. Pharmacol., 226 97 Tetrud and Langston (1989), The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease; Science, 245 519 Tatton and Greenwood (1991), Rescue of dying neurons: a new action of deprenyl in MPTP parkinsonism; J. Neurosci Res., 30 666 Tatton et al. (1994), (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis; J. Neurochem, 63 1572 Kargten et al. (1998), Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl; J. Biol. Chem., 273 5821
-20°C
TARGET: Monoamine oxidase -- PATHWAY: Apoptosis inhibitor -- RESEARCH AREA: Neuroscience; Cell death -- DISEASE AREA: Neurodegeneration; Mood disorders